Although recent rulings in Affymetrix Inc.'s 1998 patent infringement litigation against Incyte Genomics Inc. tend to favor INCY, the court has left on the table the claims of one AFFX patent that potentially cover INCY's marketed cDNA array products. Thus investors may not know the outcome for a year or more.

Most recently